Articles about 'MRC Cancer Unit'

10 Cambridge spinouts on putting their research into practice to improve outcomes for cancer patients - and why Cambridge is a great place to do this.    

Professor Dame Jocelyn Bell Burnell has become only the second woman to be awarded the Royal Society’s prestigious Copley Medal, the world’s oldest scientific prize.

Abnormal cells that develop into oesophageal cancer – cancer that affects the tube connecting the mouth and stomach – start life as cells of the stomach, according to scientists at the University of Cambridge.

A new way to identify tumours that could be sensitive to particular immunotherapies has been developed using data from thousands of NHS cancer patient samples sequenced through the 100,000 Genomes Project. 

Artificial intelligence ‘deep learning’ techniques can be used to triage suspected cases of Barrett oesophagus, a precursor to oesophageal cancer, potentially leading to faster and earlier diagnoses, say researchers at the University of Cambridge.

They juggled their jobs and sacrificed sleep to volunteer at the Cambridge Testing Centre, a collaboration between the University, AstraZeneca and GSK to support the national effort to boost COVID-19 testing. They say they were simply fulfilling their duty as scientists. Meet the volunteers behind the masks.

DNA from tissue biopsies taken from patients with Barrett’s oesophagus – a risk factor for oesophageal cancer – could show which patients are most likely to develop the disease eight years before diagnosis, suggests a study led by researchers at the University of Cambridge and EMBL’s European Bioinformatics Institute (EMBL-EBI).

A ‘pill on a string’ test can identify ten times more people with Barrett’s oesophagus than the usual GP route, after results from a 3-year trial were published in the medical journal The Lancet.

Eight Cambridge researchers - six from the University of Cambridge and two from the MRC Laboratory of Molecular Biology - are among the 63 scientists from around the world elected this year as Members and Associate Members of the European Molecular Biology Organisation (EMBO).

Cambridge scientists are set to benefit from a major cash injection from Cancer Research UK and partners to develop radical new strategies and technologies to detect cancer at its earliest stage.